Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma.

被引：0
|
作者：
Palumbo, A [1 ]
Giaccone, L [1 ]
Bertola, A [1 ]
Bringhen, S [1 ]
Rus, C [1 ]
Triolo, S [1 ]
Pileri, A [1 ]
Boccadoro, M [1 ]
机构：
[1] Univ Turin, Sezione Ematol, Dipartimento Oncol, Turin, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5004
引用
收藏
页码：292B / 292B
页数：1
相关论文
共 50 条
  • [21] Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma
    Castelli, Roberto
    Gallipoli, Paolo
    Gidaro, Antonio
    Maddalena, Wu
    Arquati, Massimo
    Deliliers, Giorgio Lambertenghi
    BLOOD, 2015, 126 (23)
  • [22] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Sung Sook Lee
    Cheolwon Suh
    Bong-Seog Kim
    Jooseop Chung
    Young-Don Joo
    Hun-Mo Ryoo
    Young Rok Do
    Jong-Youl Jin
    Hye Jin Kang
    Gyeong-Won Lee
    Moon Hee Lee
    Hyeok Shim
    Kihyun Kim
    Sung-Soo Yoon
    Soo Mee Bang
    Ho Young Kim
    Je-Jung Lee
    Jinny Park
    Dong Soon Lee
    Jae-Hoon Lee
    Annals of Hematology, 2010, 89 : 905 - 912
  • [23] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Lee, Sung Sook
    Suh, Cheolwon
    Kim, Bong-Seog
    Chung, Jooseop
    Joo, Young-Don
    Ryoo, Hun-Mo
    Do, Young Rok
    Jin, Jong-Youl
    Kang, Hye Jin
    Lee, Gyeong-Won
    Lee, Moon Hee
    Shim, Hyeok
    Kim, Kihyun
    Yoon, Sung-Soo
    Bang, Soo Mee
    Kim, Ho Young
    Lee, Je-Jung
    Park, Jinny
    Lee, Dong Soon
    Lee, Jae-Hoon
    ANNALS OF HEMATOLOGY, 2010, 89 (09) : 905 - 912
  • [24] Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma
    Richter, Joshua R.
    Bilotti, Elizabeth
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Anand, Palka
    McNeill, Ann
    Bednarz, Urszula
    Graef, Thorsten
    Vesole, David H.
    Siegel, David S.
    BLOOD, 2011, 118 (21) : 1706 - 1706
  • [25] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Mark, Tomer Martin
    Rodriguez, Melissa
    Shah, Manan
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma.
    Wang, M.
    Knight, R.
    Dimopoulos, M.
    Siegel, D.
    Rajkumar, S. V.
    Facon, T.
    Yu, Z.
    Zeldis, J.
    Olesnyckyj, M.
    Weber, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 427S - 427S
  • [28] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma.
    Guglielmelli, T
    Capella, S
    Mattioli, G
    Guerrasio, A
    Saglio, G
    BLOOD, 2003, 102 (11) : 383B - 383B
  • [30] Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma.
    Kropff, MH
    Innig, G
    Mitterer, M
    Straka, C
    Ostermann, H
    Koch, OM
    Berdel, WE
    Kienast, J
    BLOOD, 2000, 96 (11) : 168A - 168A
12345